SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Financials Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.
Equities
2196
CNE100001M79
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.96 HKD | -4.28% |
|
-3.28% | -23.76% |
| 15/05 | Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment | MT |
| 15/05 | China Approves Clinical Trials For Breast Cancer Drugs | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 65,086 | 1,25,791 | 1,13,862 | 86,922 | 61,592 | 57,421 | - | - |
| Enterprise Value (EV) 1 | 77,050 | 1,39,217 | 1,27,150 | 1,00,183 | 80,958 | 72,886 | 75,145 | 72,038 |
| P/E ratio | 20.5 x | 37.8 x | 26.5 x | 24.6 x | 28.1 x | 20.1 x | 15.3 x | 13.7 x |
| Yield | 1.47% | 0.8% | 1.14% | 1.19% | 1.08% | 1.57% | 2.02% | 2.54% |
| Capitalization / Revenue | 2.28 x | 4.15 x | 2.92 x | 1.98 x | 1.49 x | 1.29 x | 1.14 x | 1.07 x |
| EV / Revenue | 2.7 x | 4.59 x | 3.26 x | 2.28 x | 1.96 x | 1.64 x | 1.49 x | 1.34 x |
| EV / EBITDA | 13.1 x | 22.2 x | 15.7 x | 14.5 x | 13.1 x | 10.4 x | 9.63 x | 9.75 x |
| EV / FCF | -109 x | -75 x | -137 x | -64.1 x | -42.3 x | 15.7 x | 48.9 x | 43.3 x |
| FCF Yield | -0.92% | -1.33% | -0.73% | -1.56% | -2.36% | 6.37% | 2.05% | 2.31% |
| Price to Book | 2.14 x | 3.74 x | 3.21 x | 2.11 x | 1.46 x | 1.31 x | 1.2 x | 1.16 x |
| Nbr of stocks (in thousands) | 25,62,899 | 25,62,899 | 25,62,899 | 26,72,157 | 26,72,399 | 26,72,399 | - | - |
| Reference price 2 | 26.60 | 53.99 | 48.94 | 35.24 | 25.03 | 23.81 | 23.81 | 23.81 |
| Announcement Date | 30/03/20 | 29/03/21 | 22/03/22 | 27/03/23 | 26/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 28,585 | 30,307 | 39,005 | 43,952 | 41,400 | 44,429 | 50,502 | 53,609 |
| EBITDA 1 | 5,874 | 6,282 | 8,105 | 6,889 | 6,160 | 6,999 | 7,802 | 7,390 |
| EBIT 1 | 4,494 | 4,721 | 6,314 | 4,657 | 3,308 | 3,649 | 4,648 | 4,763 |
| Operating Margin | 15.72% | 15.58% | 16.19% | 10.59% | 7.99% | 8.21% | 9.2% | 8.88% |
| Earnings before Tax (EBT) 1 | 4,526 | 4,678 | 6,054 | 4,574 | 3,265 | 4,328 | 5,563 | 6,381 |
| Net income 1 | 3,322 | 3,663 | 4,735 | 3,731 | 2,386 | 3,140 | 4,124 | 4,595 |
| Net margin | 11.62% | 12.09% | 12.14% | 8.49% | 5.76% | 7.07% | 8.17% | 8.57% |
| EPS 2 | 1.300 | 1.430 | 1.850 | 1.430 | 0.8900 | 1.185 | 1.561 | 1.734 |
| Free Cash Flow 1 | -705.7 | -1,857 | -926.7 | -1,564 | -1,913 | 4,645 | 1,537 | 1,662 |
| FCF margin | -2.47% | -6.13% | -2.38% | -3.56% | -4.62% | 10.46% | 3.04% | 3.1% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 66.38% | 19.7% | 22.49% |
| FCF Conversion (Net income) | - | - | - | - | - | 147.92% | 37.27% | 36.17% |
| Dividend per Share 2 | 0.3900 | 0.4300 | 0.5600 | 0.4200 | 0.2700 | 0.3750 | 0.4817 | 0.6039 |
| Announcement Date | 30/03/20 | 29/03/21 | 22/03/22 | 27/03/23 | 26/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11,957 | 10,382 | 10,893 | 10,270 | 12,341 | 10,871 | 10,445 | 9,305 | 10,699 | 10,157 | 10,889 | 10,631 | 11,279 | 10,475 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 1,615 | 863.1 | 1,136 | 1,046 | 1,064 | 1,427 | 1,255 | 659.6 | -34.69 | 1,021 | 363.7 | 867.5 | 456 | 706.2 | - |
| Operating Margin | 13.5% | 8.31% | 10.43% | 10.18% | 8.62% | 13.13% | 12.02% | 7.09% | -0.32% | 10.06% | 3.34% | 8.16% | 4.04% | 6.74% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.4600 | 0.1800 | 0.4200 | 0.3500 | 0.4800 | 0.3700 | 0.3000 | 0.1900 | 0.0400 | 0.2300 | 0.3050 | 0.3900 | 0.3050 | 0.1800 | 0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22/03/22 | 26/04/22 | 29/08/22 | 30/10/22 | 27/03/23 | 28/04/23 | 29/08/23 | 30/10/23 | 26/03/24 | 29/04/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 11,964 | 13,426 | 13,289 | 13,261 | 19,366 | 15,465 | 17,724 | 14,617 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.037 x | 2.137 x | 1.639 x | 1.925 x | 3.144 x | 2.21 x | 2.272 x | 1.978 x |
| Free Cash Flow 1 | -706 | -1,857 | -927 | -1,564 | -1,913 | 4,645 | 1,537 | 1,662 |
| ROE (net income / shareholders' equity) | 11.6% | 10.8% | 12.4% | 9.04% | 5.29% | 6.41% | 8.03% | 8.83% |
| ROA (Net income/ Total Assets) | 4.53% | 4.58% | 5.35% | 3.73% | 2.18% | 2.6% | 2.9% | 3.3% |
| Assets 1 | 73,341 | 79,904 | 88,433 | 1,00,022 | 1,09,663 | 1,20,786 | 1,42,401 | 1,39,215 |
| Book Value Per Share 2 | 12.40 | 14.40 | 15.30 | 16.70 | 17.10 | 18.20 | 19.80 | 20.60 |
| Cash Flow per Share 2 | 1.260 | 1.010 | 1.540 | 1.580 | 1.280 | 2.700 | 1.760 | 2.000 |
| Capex 1 | 3,928 | 4,437 | 4,875 | 5,782 | 5,328 | 5,632 | 3,919 | 4,577 |
| Capex / Sales | 13.74% | 14.64% | 12.5% | 13.15% | 12.87% | 12.68% | 7.76% | 8.54% |
| Announcement Date | 30/03/20 | 29/03/21 | 22/03/22 | 27/03/23 | 26/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.81
CNY
Average target price
28.61
CNY
Spread / Average Target
+20.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.35% | 705B | |
| +29.39% | 583B | |
| -3.49% | 364B | |
| +20.15% | 332B | |
| +6.19% | 291B | |
| +14.11% | 238B | |
| -3.03% | 210B | |
| +10.02% | 209B | |
| +9.21% | 169B |
- Stock Market
- Equities
- 600196 Stock
- 2196 Stock
- Financials Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
